Search
Search Results
-
-
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
BackgroundDistinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has...
-
Aripiprazole as protector against COVID-19 mortality
The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To...
-
Administration of Aripiprazole Alleviates Memory Impairment and Restores Damaged Glutamatergic System in 5xFAD Mice
PurposeMany patients with Alzheimer's disease (AD) also have psychosis, and it has been reported that these patients have more severely impaired...
-
Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports
BackgroundSignificant elevation of creatine kinase levels (above three digits) and leucocytosis in the absence of muscle rigidity, tremors, or...
-
Randomized, double-blind, placebo-controlled trial of aripiprazole oral solution in children and adolescents with Tourette’s disorder
BackgroundAripiprazole is the most frequently recommended antipsychotic for the treatment of tics in children and adolescents with Tourette’s...
-
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review
Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not...
-
Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial
RationaleThe efficacy and safety of antidepressant augmentation therapy with aripiprazole (AATA) has been established; however, the ongoing effects...
-
The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors
Antipsychotic drugs are the mainstay of treatment for schizophrenia and provide adjunct therapies for other prevalent psychiatric conditions,...
-
Adis summary of research: Safety, tolerability and pharmacokinetics of aripiprazole 2-monthly formulation in patients with schizophrenia or bipolar I disorder
The once-monthly long-acting injectable (LAI) formulation of aripiprazole, an atypical antipsychotic that stabilizes the dopamine-serotonin system,...
-
Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports
Aripiprazole is an efficacious treatment for both the positive and negative symptoms of schizophrenia and is also commonly used as a mood stabilizer....
-
Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients
Aripiprazole is recommended for routine use in schizophrenia patients. However, the biological mechanism for the adverse drug reactions (ADRs) among...
-
The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole
Aripiprazole (Abilify®), a carbostyril derivative, is an antipsychotic with a new mechanism of action that differs from those of existing dopamine D2...
-
Spectrofluorometric quantitative analysis of aripiprazole based on quenching of natural derived carbon quantum dots in spiked human plasma
Autism spectrum disorder is a significant concern worldwide, particularly in Middle Eastern countries. Aripiprazole, a psychiatric medicine that...
-
Oral aripiprazole in the treatment of tic disorders in China: a cost-effectiveness analysis based on a mapping algorithm derived from a Chinese children and adolescents population
BackgroundOral aripiprazole exhibits favorable clinical efficacy and safety in the suppression of tics in children and adolescents with tic...
